Rezdiffra (Resmetirom): What People Actually Pay

Resmetirom is the generic name for Rezdiffra, an oral thyroid hormone receptor-beta agonist taken once daily and manufactured by Madrigal Pharmaceuticals. The FDA approved it in March 2024 as the first drug specifically indicated for metabolic dysfunction-associated steatohepatitis (MASH, formerly called NASH) in adults with moderate to advanced liver fibrosis, stages F2 or F3, generally alongside diet and exercise. It is not approved for simple fatty liver, F1 fibrosis, or cirrhosis (F4).

The direct answer: Rezdiffra's listed wholesale acquisition cost is reported at roughly $3,950 per month (about $47,400 per year), but that number describes almost no one's actual bill. Commercially insured patients who enroll in Madrigal's copay assistance program commonly report monthly costs at or near $0, while patients without insurance or assistance, and Medicare beneficiaries in the early part of the year, can face costs in the thousands of dollars per month until a benefit cap or copay program takes effect. This gap between list price and real-world payment is the single most important thing to understand before assuming the drug is unaffordable, and it should be treated as a snapshot as of 2026 rather than a fixed fact, since manufacturer pricing and program terms change over time.

What is verified, what is reported, and what needs confirmation

This article draws on two kinds of evidence, and they should not be blended together. The first is regulatory and institutional: the FDA's approval announcement and the official prescribing information, which establish the indication, dosing framework, and approved safety data. The second is reported experience: pricing figures, copay program terms, and patient accounts circulating in media coverage, manufacturer materials, and online forums. The second category is useful for setting expectations but is not clinical evidence and is not independently verified in the sources available for this article. Where a specific dollar figure or trial percentage could not be confirmed against a primary, currently accessible source, it is described in general terms below rather than presented as a precise, citable number.

What does Rezdiffra actually cost before insurance?

Rezdiffra's wholesale acquisition cost has been widely reported at approximately $47,400 per year, or about $3,950 for a 30-day supply, since its 2024 launch. This places it well above older off-label options for MASH, such as vitamin E or pioglitazone, which cost under $30 a month, and it reflects the fact that payers have no generic alternative to reference when negotiating coverage. List price is a starting point for insurance negotiations and cost-sharing calculations, not what most insured patients pay out of pocket. Anyone comparing this figure to a personal quote should confirm current pricing directly with a specialty pharmacy, since WAC figures can change and are not something this article can verify in real time.

How much do commercially insured patients report paying?

Patients with commercial or employer-sponsored insurance who enroll in Madrigal's copay assistance program have reported monthly costs as low as $0, with the program reportedly covering up to $13,000 per year in out-of-pocket costs for eligible patients. This detail comes from manufacturer program materials and patient reports rather than a peer-reviewed source, and eligibility rules (income, insurance type, program caps) should be confirmed directly with Madrigal's patient support line or a specialty pharmacy before a patient counts on a specific number.

Without the copay card, coinsurance on a specialty tier (commonly 25% to 33% of cost) could mean monthly out-of-pocket costs in the range of roughly $1,000 to $1,300 before a plan's out-of-pocket maximum is reached. Some health plans use copay accumulator or maximizer programs that prevent manufacturer assistance dollars from counting toward a patient's deductible or out-of-pocket maximum. Where this applies, a patient could exhaust the copay card's annual benefit and still owe a substantial balance later in the year. Patients should ask their plan directly whether an accumulator program applies, since this single detail changes the total annual cost more than almost any other variable.

What does Medicare Part D coverage look like?

Manufacturer copay cards generally cannot be used with federal insurance programs, including Medicare Part D. Rezdiffra's specialty-tier placement in most Part D formularies means beneficiaries are typically responsible for coinsurance during the initial coverage phase. Under the Inflation Reduction Act, Medicare Part D enrollees have had a $2,000 annual out-of-pocket cap on covered drug costs since January 2025, an established federal policy change rather than a manufacturer benefit. Because Rezdiffra's cost-sharing is high relative to that cap, a Medicare patient could reach the $2,000 ceiling within the first few months of therapy and then owe nothing for the medication for the rest of the calendar year. Madrigal has also described a separate needs-based assistance track for Medicare and Medicaid patients, though public eligibility and approval-rate data are not available.

Why does prior authorization take so long, and does a biopsy help or hurt?

Most commercial and Medicare Part D plans require prior authorization for Rezdiffra, and the documentation standard is stricter than many prescribers or patients expect. Plans commonly ask for evidence of MASH with fibrosis stage F2 or F3, and biopsy-confirmed fibrosis staging is frequently the most readily accepted form of documentation, though some plans also accept vibration-controlled transient elastography (FibroScan) results within a plan-defined liver stiffness range. Because liver biopsy carries procedural risk, added cost, and scheduling delays, patients and prescribers report a common bottleneck: a clinical diagnosis of MASH exists, but the payer denies or delays authorization pending histological confirmation the patient has not yet undergone. Some plans also require a documented trial of lifestyle intervention or vitamin E before approving Rezdiffra. Patients should ask their prescriber, before the first prescription is written, exactly which documentation their specific plan requires and whether elastography is an accepted substitute for biopsy.

What does the trial evidence behind the price actually show?

Rezdiffra's approval rests on a phase 3 randomized trial (MAESTRO-NASH) in patients with biopsy-confirmed MASH and fibrosis. The trial reported that a meaningfully higher proportion of patients on resmetirom achieved MASH resolution without worsening fibrosis at 52 weeks compared with placebo, and a higher proportion also achieved at least one stage of fibrosis improvement. LDL cholesterol reductions were also reported in the resmetirom arms, consistent with the drug's mechanism as a liver-targeted thyroid hormone receptor-beta agonist. The most commonly reported side effects were gastrointestinal, including diarrhea and nausea, generally described as most noticeable in the first several weeks of treatment.

The exact percentages from this trial are widely cited in secondary sources, but this article could not independently verify a specific, reliable primary link for those figures at the time of writing. Anyone relying on the precise numbers for a clinical or coverage decision should confirm them against the FDA-approved prescribing information or the FDA's approval announcement rather than this summary. Fibrosis stage is generally understood in hepatology to be strongly associated with liver-related outcomes, but the exact magnitude of that association from any single meta-analysis is not restated here without a verified source.

An outcomes trial testing whether resmetirom reduces liver-related death, transplant, or decompensation has not been completed as of this writing; MAESTRO-NASH used histological endpoints (MASH resolution, fibrosis stage) as the basis for approval, which is standard for this drug class but is a surrogate outcome, not a direct measure of long-term survival.

What are patients saying online, and how much should that weigh?

Patient reports on forums such as Reddit's liver and fatty-liver-disease communities and general drug-review sites remain limited in volume, in part because Rezdiffra has been available for a relatively short time and the diagnosed, biopsy-confirmed MASH population is smaller than communities built around more common conditions. Recurring themes in available reports include successful copay card enrollment resulting in low or no monthly cost, gastrointestinal side effects that patients describe as tolerable and improving over the first several weeks, and administrative friction from prior authorization and repeat prescription requirements.

These reports are affected by strong selection bias. Patients who obtained coverage, enrolled in assistance programs, and tolerated the drug are more likely to post than those who were denied coverage, could not afford cost-sharing, or discontinued due to side effects. The number of identifiable individual patient accounts online is small, likely in the low hundreds at most, which is not a sample size that supports population-level conclusions about typical cost or typical experience. Forum reports are useful for anticipating what the process might feel like, not for predicting an individual's actual bill or outcome.

How does Rezdiffra's cost compare to other options for MASH?

Rezdiffra is the only FDA-approved drug for MASH with fibrosis, so there is no direct in-indication price comparison. For context, GLP-1 receptor agonists such as semaglutide have shown promising results in MASH research and carry a list price roughly in the $12,000 to $16,000 per year range at approved weight-management doses, but they do not currently carry an FDA indication for MASH. Older off-label options, vitamin E and pioglitazone, cost under a few hundred dollars a year but have not demonstrated the fibrosis-improvement results seen with resmetirom in its pivotal trial. Some prescribers reportedly sequence GLP-1 therapy first for patients who also have obesity or type 2 diabetes and add resmetirom if fibrosis persists, but this combination approach has not been validated in a completed clinical trial, and its long-term cost and outcome data are not yet available.

What financial assistance actually exists right now?

Madrigal has described a CareConnect support program with separate tracks: a copay card for commercially insured patients, a free-drug pathway for uninsured patients who meet income criteria, and a needs-based process for Medicare and Medicaid patients. As of the information available for this article, major independent charitable copay foundations had not established a dedicated Rezdiffra fund, though this can change as prescribing volume grows, and patients should check current foundation listings directly rather than relying on this article's snapshot. Specialty pharmacies often provide benefits-investigation services that can identify alternate coverage pathways for patients who are initially denied.

What does the first 90 days typically involve?

After prior authorization is approved, a specialty pharmacy typically dispenses a 30-day supply, with dosing based on body weight per the FDA label. Baseline and follow-up laboratory monitoring, including thyroid function tests and a lipid panel, is part of the prescribing information's recommended monitoring schedule. Gastrointestinal side effects are most often reported in the first several weeks. Because the trial's histological endpoints were measured at 52 weeks, patients and prescribers generally need to commit to roughly a year of therapy before the drug's primary fibrosis-related benefit can be reassessed, typically with a repeat biopsy or elastography study, which is itself an additional cost that should be confirmed with the insurer in advance.

A framework for weighing what you read about Rezdiffra's cost and results

Use this to sort any specific cost or outcome claim you encounter, whether from this article, a forum post, or a sales rep, into what it can and cannot tell you.

The recurring failure mode this table is built to prevent: treating a manufacturer program figure, a forum anecdote, or a remembered trial percentage as if it were a verified, individually applicable number. Each row above sits at a different level of evidence, and none of them substitutes for a direct conversation with your prescriber, insurer, and specialty pharmacy about your specific plan and diagnosis.

What is established, what is plausible, and what remains unproven

Established: Rezdiffra is FDA-approved for MASH with F2 or F3 fibrosis, is dosed once daily based on body weight, and its pivotal trial used histological (biopsy-based) endpoints at 52 weeks rather than long-term survival outcomes. A federal $2,000 annual out-of-pocket cap has applied to Medicare Part D drug spending since January 2025.

Plausible but not confirmed by this article's sources: exact list price and typical net out-of-pocket figures reported in media and manufacturer materials, the precise trial percentages for MASH resolution and fibrosis improvement, and the degree to which LDL reductions translate into a real cardiovascular benefit.

Not established: how Rezdiffra affects long-term outcomes such as liver-related mortality, decompensation, or transplant risk; the real-world cost and outcome of combining resmetirom with a GLP-1 agonist; and population-level patterns in online patient reports, which come from too small and too self-selected a group to generalize from.

If a specific dollar amount or trial statistic matters for a real financial or medical decision, verify it against the current FDA label, the manufacturer's official program materials, and your own insurer, rather than this summary.

Note for editorial and medical review: this article previously included attributed quotations from named physicians and precise clinical-trial percentages that could not be verified against an accessible primary source during this revision. Those quotations have been removed, and the trial results have been described in general terms pending confirmation against the current FDA label or a verified primary publication. This draft has not undergone qualified medical review.